We’re excited to share that City Therapeutics won Emerging Company of the Year at New England VC’s 13th Annual #NEVYs25! It’s a meaningful moment for our team as we continue advancing RNAi therapeutics with purpose, care, and recognized momentum.

Excited to announce the submission of our CTA to the @mhragovuk.bsky.social to initiate a Phase 1 study of CITY-FXI, an investigational RNAi therapeutic targeting Factor XI w/ the potential to safely & effectively prevent blood clots without increasing bleeding risk. www.citytx.com/news/city-th...

Honored to be named by LinkedIn as a Top 10 #LinkedInTopStartups of Boston in 2025! In the heart of Kendall Square, we’re building a place where careers & cutting-edge RNAi science can thrive. www.linkedin.com/pulse/linked...

One year strong, from growing our team to building partnerships, our focus is unwavering to reshape the future of RNAi medicines. Here's to what's next!

Check out City's Executive Chair, @jmaraganore.bsky.social presenting at Fierce Biotech Week 2025 this week, where he'll offer insights from his past and reflect on the evolving landscape of RNAi! www.fiercebiotechweek.com/event/fierce...

Exciting news from City! We’ve partnered with Biogen to develop select novel RNAi-based therapies leveraging our next-generation RNAi engineering technologies. Learn more: www.globenewswire.com/news-release...

Excited to welcome Baisong Mei, M.D., Ph.D., as CMO, Anna O’Driscoll as CHRO, and Sara Nochur, Ph.D., as an independent board member! Their expertise in life sciences will help drive our next phase of growth. Learn more below and at: www.businesswire.com/news/home/20...